Share this postAntifragile Thinking3Q FY25 analysis and next steps: FDC, Fairchem, Orchid Pharma, Vimta Labs, DMCCCopy linkFacebookEmailNotesMorePlayback speed×Share postShare post at current timeShare from 0:000:00/0:00Transcript142Share this postAntifragile Thinking3Q FY25 analysis and next steps: FDC, Fairchem, Orchid Pharma, Vimta Labs, DMCCCopy linkFacebookEmailNotesMore3243Q FY25 analysis and next steps: FDC, Fairchem, Orchid Pharma, Vimta Labs, DMCCSajal KapoorFeb 12, 2025142Share this postAntifragile Thinking3Q FY25 analysis and next steps: FDC, Fairchem, Orchid Pharma, Vimta Labs, DMCCCopy linkFacebookEmailNotesMore324ShareTranscriptDiscussion about this videoCommentsRestacksShare this postAntifragile Thinking3Q FY25 analysis and next steps: FDC, Fairchem, Orchid Pharma, Vimta Labs, DMCCCopy linkFacebookEmailNotesMoreAntifragile Thinking PodcastSajal Kapoor's SubstackAuthor of 'Framing Business Uncertainty'Twitter @unseenvalueSajal Kapoor's Substack Author of 'Framing Business Uncertainty' Twitter @unseenvalueSubscribeListen onSubstack AppRSS FeedAppears in episodeSajal KapoorRecent EpisodesRQT: Backward Integration and Chemical vs Pharma Fixed Asset Turns Aug 3 • Sajal KapoorAddendum: Sector Agnostic SIP Framework Jul 29 • Sajal KapoorSector Agnostic SIP FrameworkJul 27 • Sajal KapoorMy Trust with Biosciences: Panacea BioJul 17 • Sajal KapoorValuation Masterclass Series: Role of Reframing and Rethinking! (Part - 2)Jul 17 • Sajal KapoorValuation Masterclass Series: The Art of Parsing the Management (Part 1) Jul 14 • Sajal KapoorPiramal Pharma: Why and When?Jul 11 • Sajal KapoorAnthem Biosciences: IPO and Scenario AnalysisJul 9 • Sajal Kapoor
Share this post